Claudio Ceconi
YOU?
Author Swipe
View article: New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2023
New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2023 Open
Although cardiovascular diseases (CVDs) are the leading cause of death worldwide, their pharmacotherapy remains suboptimal. Thus, there is a clear unmet need to develop more effective and safer pharmacological strategies. In this review, w…
View article: New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2022
New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2022 Open
Cardiovascular diseases (CVD) remain the leading cause of death worldwide, and pharmacotherapy of most of them is suboptimal. Thus, there is a clear unmet clinical need to develop new pharmacological strategies with greater efficacy and be…
View article: Sex differences in arterial hypertension
Sex differences in arterial hypertension Open
There is strong evidence that sex chromosomes and sex hormones influence blood pressure (BP) regulation, distribution of cardiovascular (CV) risk factors and co-morbidities differentially in females and males with essential arterial hypert…
View article: Facing the challenge of polypharmacy when prescribing for older people with cardiovascular disease. A review by the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy
Facing the challenge of polypharmacy when prescribing for older people with cardiovascular disease. A review by the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy Open
Population ageing has resulted in an increasing number of older people living with chronic diseases (multimorbidity) requiring five or more medications daily (polypharmacy). Ageing produces important changes in the cardiovascular system an…
View article: Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology
Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology Open
The heart failure epidemic is growing and its prevention, in order to reduce associated hospital readmission rates and its clinical and economic burden, is a key issue in modern cardiovascular medicine. The present position paper aims to p…
View article: Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology
Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology Open
The heart failure epidemic is growing and its prevention, in order to reduce associated hospital readmission rates and its clinical and economic burden, is a key issue in modern cardiovascular medicine. The present consensus document aims …
View article: Update on management of hypokalaemia and goals for the lower potassium level in patients with cardiovascular disease: a review in collaboration with the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy
Update on management of hypokalaemia and goals for the lower potassium level in patients with cardiovascular disease: a review in collaboration with the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy Open
Hypokalaemia is common in patients with cardiovascular disease. In this review, we emphasize the importance of tight potassium regulation in patients with cardiovascular disease based on findings from observational studies. To enhance the …
View article: Les liaisons dangereuses and the danger of deductions: The interplay between cardiovascular disease and COVID-19
Les liaisons dangereuses and the danger of deductions: The interplay between cardiovascular disease and COVID-19 Open
interplay between cardiovascular disease and COVID-19
View article: 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD Open
International audience
View article: Reasons for disparity in statin adherence rates between clinical trials and real-world observations: a review
Reasons for disparity in statin adherence rates between clinical trials and real-world observations: a review Open
With statins, the reported rate of adverse events differs widely between randomized clinical trials (RCTs) and observations in clinical practice, the rates being 1-2% in RCTs vs. 10-20% in the so-called real world. One possible explanation…
View article: Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology
Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology Open
Renin angiotensin aldosterone system inhibitors/antagonists/blockers (RAASi) are a cornerstone in treatment of patients with cardiovascular diseases especially in those with heart failure (HF) due to their proven effect on surrogate and ha…
View article: Non-insulin antidiabetic pharmacotherapy in patients with established cardiovascular disease: a position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy
Non-insulin antidiabetic pharmacotherapy in patients with established cardiovascular disease: a position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy Open
Review of The aim of antidiabetic pharmacotherapy in patients with type 2 diabetes and cardiovascular disease with emphasis on non-insulin compuonds
View article: Comprehensive efforts to increase adherence to statin therapy
Comprehensive efforts to increase adherence to statin therapy Open
There is compelling evidence that statin therapy improves cardiovascular morbidity and mortality. Unfortunately, statin adherence is far from optimal regarding initiation, execution and persistence of treatment over time.26 Poor adherence …
View article: Gender differences in the effects of cardiovascular drugs
Gender differences in the effects of cardiovascular drugs Open
Although sex-specific differences in cardiovascular medicine are well known, the exact influences of sex on the effect of cardiovascular drugs remain unclear. Women and men differ in body composition and physiology (hormonal influences dur…
View article: Erratum to “Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency” [Eur J Heart Fail 2016;18:482‐489]
Erratum to “Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency” [Eur J Heart Fail 2016;18:482‐489] Open
The publisher regrets that in the review article, Prof. Stefan D. Anker and Prof. Stefan Schroeder's affiliation were incorrectly published. The corrected version can be found above. Apologies for any inconvenience caused.
View article: Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency
Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency Open
Composite endpoints are commonly used as the primary measure of efficacy in heart failure clinical trials to assess the overall treatment effect and to increase the efficiency of trials. Clinical trials still must enrol large numbers of pa…